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OBJECTIVES: The aim of the present study was to investigate the effectiveness of Samarium153-particulate hydroxyapatite radiation 
synovectomy in rheumatoid arthritis patients with chronic knee synovitis. 
METHODS: Fifty-eight rheumatoid arthritis patients (60 knees) with chronic knee synovitis participated in a controlled double-
blinded trial. Patients were randomized to receive either an intra-articular injection with 40 mg triamcinolone hexacetonide alone 
(TH group) or 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium153-particulate hydroxyapatite (Sm/TH group). 
Blinded examination at baseline (T0) and at 1 (T1), 4 (T4), 12 (T12), 32 (T32), and 48 (T48) weeks post-intervention were performed 
on all patients and included a visual analog scale for joint pain and swelling as well as data on morning stiffness, flexion, extension, 
knee circumference, Likert scale of improvement, percentage of improvement, SF-36 generic quality of life questionnaire, Stanford 
Health Assessment Questionnaire (HAQ), Lequesne index, use of non-steroidal anti-inflammatory drugs or oral corticosteroids, 
events and adverse effects, calls to the physician, and hospital visits. 
RESULTS: The sample was homogeneous at baseline, and there were no withdrawals. Improvement was observed in both groups 
in relation to T0, but no statistically significant differences between groups were observed regarding all variables at the time points 
studied. The Sm/TH group exhibited more adverse effects at T1 (p<0.05), but these were mild and transitory. No severe adverse ef-
fects were reported during follow-up. 
CONCLUSION: Intra-articular injection of Samarium153-particulate hydroxyapatite (15 mCi) with 40 mg of triamcinolone hexace-
tonide is not superior to triamcinolone hexacetonide alone for the treatment of knee synovitis in patients with rheumatoid arthritis at 
1 y of follow-up.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic disease that 
is mainly characterized by asymmetric erosive synovitis, 
particularly affecting peripheral joints.1 Functional disability 
in patients with RA is the consequence of joint deformity, 
which is the result of pannus invasion of the articular 
cartilage, capsule, ligaments and subchondral bone.2 Current 
treatment for RA is based on a pharmacological approach,3 
physical therapy,4 and patient education.5 Synovectomy 
through chemical, radioisotopic, or surgical means has been 
adopted as a therapeutic option in RA.6,7 Most chemical 
synovectomy is performed using intra-articular injection 
(IAI) of glucocorticosteroids, the most effective of which has 1188
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been shown to be triamcinolone hexacetonide (TH).8
Radiation synovectomy (RS) (also called radio-
synoviorthesis or radiosynovectomy) is a local IAI of 
radionuclides in colloidal form for radiotherapy. First 
used by Fellinger et al.9 in 1952, the technique has been 
applied for over 50 y in the treatment of resistant synovitis 
in individual joints after the failure of long-term systemic 
pharmacotherapy and intra-articular steroid injections. 
Radioisotopes with emission of β radiation have the capacity 
to diminish the inflammatory process and ablate the inflamed 
synovial membrane (pannus) with subsequent fibrosis.10 
Three radionuclides are currently in use: Yttrium-90 
(90Y-silicate/citrate), Rhenium-186 (186Re-sulfide), and 
Erbium-169 (169Er citrate), which have been indicated 
for large, medium, and small joints, respectively.10 These 
radionuclides are indicated for treatment of joint pain arising 
from arthropathies, including RA, spondyloarthropathy, 
other inflammatory joint diseases (Lyme disease, Behçet’s 
disease), persistent synovial effusion, hemophilic arthritis, 
calcium pyrophosphate dihydrate arthritis, pigmented 
villonodular synovitis, and undifferentiated arthritis.10,12
In clinical practice, RS is a procedure that has been 
widely used for several decades, mainly in European 
countries, Australia, and Canada,11 especially for patients 
with refractory synovitis, (synovitis that fails to respond to 
at least one intra-articular injection with corticosteroids).12
Despite the established use of RS in clinical practice, 
there are few randomized, controlled studies using this 
technique in relation to the most often used radioisotopes: 
186Re,  169Er and  90Y.7,10,12-24 Samarium153-hydroxyapatite 
(153SmPHYP) is considered another option for RS25,26; 
however, there are few well-conducted studies in the 
literature using  153SmPHYP for the treatment of chronic 
synovitis. Therefore, we decided to develop a randomized 
controlled double-blinded study that aimed to investigate the 
effectiveness of 153SmPHYP in RS for chronic knee synovitis 
in patients with RA.
PATIENTS AND METHODS
A controlled, randomized, double-blind prospective 
study was carried out comparing RS to  153SmPHYP 
associated with TH versus IAI with TH alone for the 
treatment of knee synovitis in patients with RA. 
Patients
This study included 58 consecutive patients (60 
joints) with RA and chronic knee synovitis. Patients were 
recruited from the Rheumatology Outpatient Clinics at the 
Universidade Federal de São Paulo (UNIFESP), São Paulo, 
Brazil. The following were the inclusion criteria: diagnosis 
of RA (according to the ACR criteria) at least 6 mo prior 
to recruitment;27 chronic monoarticular knee synovitis 
or oligoarticular arthritis with the knee being the more 
symptomatic joint for over 6 wks; age between 18 and 60 y; 
use of stable doses of oral corticosteroids for the previous 30 
d and use of stable doses of DMARDs (disease modifying 
antirheumatic drugs) for the previous 3 mo; a score between 
5 and 10 on a visual analog scale for pain (VAS, range 0-10 
cm); reading and writing skills; and no risk of pregnancy 
(women with a history of hysterectomy, tubal ligation, or 
menopause). Written informed consent was obtained from 
all subjects, and the Ethics Committee approved the study. 
Exclusion criteria were as follows: patients with collagen 
diseases other than RA; pregnant or breast-feeding women; 
intra-articular knee injection in the previous 3 mo (or 
other joints); prior knee surgery or skin lesion; suspected 
septic arthritis or ruptured popliteal cyst (knee); urinary 
incontinence; any intervention in the knee in the previous 3 
mo. Radiographs were performed with loads on the knees 
submitted to the procedure at the beginning of the study 
and later classified through “blinded” radiographic analysis 
according to the Kellgren-Lawrence scale for secondary 
osteoarthritis.28
After a period of 3 mo of follow-up, the patients could 
have their DMARDs modified. We opted for that flexibility 
in order to provide better clinical control of the disease and 
to increase the adherence of the patients. 
Intervention
Lots with opaque sealed envelopes were used to 
randomly and equally allocate patients into two intervention 
groups: TH group, in which 30 patients (30 knees) received 
an IAI in the knee with 40 mg triamcinolone hexacetonide 
(TH) alone; and Sm/TH group, in which 28 patients 
(30 knees) received 40 mg TH combined with 15 mCi 
153SmPHYP. Both procedures were performed by the same 
researcher, and assessments were carried out by a blinded 
evaluator. In the case of bilateral synovitis, the knee with the 
higher visual analogue score (VAS) for pain was infiltrated. 
Inclusion of the same patient in the study for a second time 
was permitted if he/she fulfilled the inclusion criteria after 
three months from the initial intervention and exhibited 
arthritis in the contralateral knee. Inclusion a second time 
for the same knee was not permitted.
153SmPHYP was provided by the “Instituto de Pesquisas 
Energéticas e Nucleares do Brasil” (IPEN). Both types 
of intervention were performed in the Nuclear Medicine 
Section following the bio-safety rules  10 for the use of 
radioactive material. Procedures were always performed 1189
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in the same fluoroscopy room. Threaded syringes were 
connected to a three-way tap and 50 x 8 mm needles were 
used to avoid reflux of the injected medication.
Procedure 
Each patient underwent IAI guided by fluoroscopy 
while lying comfortably on their back. The knee was 
positioned at maximum extension with the needle entry 
point two centimeters from the upper-lateral angle of the 
patella subjected to eversion. Lidocaine (3 ml, 2%) with no 
vasoconstrictor was injected into the intra-articular region. 
Then, 3 to 5 ml of non-ionic iodated contrast medium was 
also injected. Distribution in the intra-articular recesses of 
the knee was viewed continuously by fluoroscopy. The Sm/
TH group received 15 mCi injections of 153SmPHYP diluted 
with 5 ml of 0.9% saline solution followed by 40 mg of TH. 
The TH group received 40 mg of TH alone.
A small amount of air was maintained in the syringe 
upon terminating infiltration so as to hinder subcutaneous 
reflux of the drugs. Systematic joint aspiration was 
performed prior to the injections in patients with synovial 
effusion. No patient had visual access to the procedure or 
preparation of the syringes.
All patients, regardless of group, remained at rest for four 
hours in a wheelchair in the Nuclear Medicine Section, and 
the knee was extended with the help of a splint.26 Patients 
were then transported to their homes and were told to 
remain at rest with a splint on the infiltrated knee for 48 h, 
only getting up from the bed to attend to their physiological 
needs.
Evaluation 
Patients were evaluated by a blinded physician at baseline 
(T0) as well as 1, 4, 12, 32, and 48 weeks after intervention 
(T1, T4, T12, T32, and T48, respectively). The following 
instruments were applied during all assessment sessions: VAS 
for joint pain and swelling (range: 0-10 cm), knee goniometry 
(flexion and extension), morning stiffness, knee circumference 
(cm), Likert scale of improvement (a lot of improvement, 
little improvement, unchanged, a little worse, much worse) 
according to the patient and the evaluator, percentage of 
improvement, Lequesne index,29 calls to the physician, 
hospital visits, and adverse effects and events.
The following assessment instruments were applied 
through T12: Brazilian version of the Functional subscale of 
the Stanford Health Assessment Questionnaire (HAQ),30 
Brazilian version of the SF-36 generic quality of life 
questionnaire,31 Lequesne index,29 and use of non-steroidal 
anti-inflammatory drugs and oral corticosteroids. 
The number of sodium diclofenac tablets and oral 
prednisone doses were counted at each time point, and 
average daily doses for these drugs were assessed. Patients 
were considered withdrawals if they interrupted the follow-
up in the first month of the study; had altered DMARDs; 
or experienced an interruption of their disease for a period 
of two weeks or more. During the three-month follow-up 
period, the DMARDs were maintained stable, whereas 
prednisone and diclofenac doses could be altered according 
to need. After this period, there was flexibility for the 
following items: physiotherapy, acupuncture, infiltrations, 
and change in DMARDs according to the needs and activity 
of the disease.
Statistical Analysis
Data are presented as mean ± standard deviation. Chi-
square analysis was used to evaluate differences between 
categorical variables. The Mann-Whitney test was used for 
analysis of non-parametric numerical variables. ANOVA 
analysis was performed to compare numerical variables 
repeated over time. The significance level was set at p<0.05. 
The Tukey multiple comparison test was performed for 
intra-group analysis. ANOVA with non-parametric repeated 
measurements was used in the analysis of ordinal data of the 
Likert scale. Data were analyzed according to the intention-
to-treat principle and patients with missing data had the 
previous evaluation data repeated.
RESULTS
The sample was made up of 58 patients (60 knees). Two 
patients participated in the study twice and were randomized 
twice (once for each knee). The second randomization 
was for the contralateral knee and occurred three months 
after the intervention for the first knee. The data displayed 
in the tables refer to the number of knees and not the 
number of patients. There was no statistically significant 
difference between groups regarding joint, functional class, 
demographic, or disease-related variables at baseline (T0) 
(Table 1). 
The radiological assessment was done according to the 
Kellgren-Lawrence scale28 and no difference was found 
between the groups, even when the groups were stratified 
into five degrees (0 to 4) according to this scale (Table 1).
Three patients were absent from the T32 reevaluation (2 
from the Sm/TH group and 1 from the TH) and four were 
absent from the T48 reevaluation (1 from the Sm/TH Group 
and 3 from the TH group).
In the intra-group analysis in relation to T0 (initial 
time), there was a statistically significant improvement at 1190
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all evaluation times for the VAS for pain and swelling; at T1 
for morning stiffness; at T1, T4, and T12 for joint flexion; at 
T1 and T4 for joint extensions; and from T4 to T48 for knee 
circumference in both groups (Table 2). In the inter-group 
analysis throughout the evolution of the study, no differences 
were observed between groups regarding the local variables 
(VAS for pain and swelling, morning stiffness, knee flexion, 
extension, and circumference) (Table 2). 
There were no statistical differences between the 
groups for the following variables: Likert scale of 
improvement according to patient and evaluator, percentage 
of improvement, HAQ (Table 3) and SF-36 questionnaires, 
Lequesne index (Table 3), use of non-steroidal anti-
inflammatory drugs and oral corticosteroids (Table 4), calls 
to the physician and hospital visits. 
Side effects were divided into two groups: adverse effects 
were those cited by either the patient or evaluator as likely 
related to the procedure; events were situations of any nature 
cited by either the patient or evaluator. Twenty-two adverse 
effects were registered in the evolution of the patients, the 
most frequent of which was post-injection flare (6.7% of 
the initial sample) with an average duration of 2.25 d (1 to 
4 d) after infiltration that did not persist through to the T1 
evaluation. The Sm/TH group exhibited more adverse effects 
than the TH group at T1 (p<0.015), but in the evaluations 
T4 to T48 the number of adverse effects was similar in both 
groups. Three of the five adverse effects (60%) in the TH 
group occurred before the T1 evaluation.
Table 1- Characteristics of the sample at baseline
Sm/TH 
Group 
(n=30)
TH Group
(n=30)
p#
Age, years (Mean±SD) 54.8 (±8.04) 54.4 (±7.4) 0.491
Gender (Women/ Men) 25:5 27:3 0.447
Race (White) 24 20 0.11
Disease duration, years (Mean±SD) 12.07 (±9.4) 13.2 (±12) 0.677
Rheumatoid Factor (positive) (%) 19 (63.3%) 20 (66.7%) 0.787
Functional class II: III 9:21 13:17 0.284
DMARDS (%) 28 (93.3%) 27 (90%) 0.640
Methotrexate (%) 24 (80%) 23 (76.6%) 0.754
Chloroquine diphosphate (%) 4 (13.3%) 4 (13.3%) 1.000
Sulfasalazine (%) 1 (3.3%) 2 (6.7%) 0.554
Leflunomide (%) 6 (20%) 8 (26.7) 0.542
Infliximab (%) 0 (0%) 1 (3.3%) 0.313
Time from past infiltration of the 
knee (months) Mean±SD
12.4 (±15.4) 15.4 (±16.9) 0.954
Kellgren-Lawrence Classification
   Grade 0
   Grade 1
   Grade 2
   Grade 3
   Grade 4
1
5
6
14
4
3
8
9
9
1
0.269
TH group: triamcinolone hexacetonide (TH); Sm/TH group: 153SmPHYP + 
TH; SD=standard deviation; #p = Pearson’s chi-square, Mann-Whitney test
Table 2 - Assessment of clinical parameters
Time Points 
(weeks)
Sm/TH Group (n=30) 
Mean±SD
TH Group 
(n=30) 
Mean±SD
Inter-group 
p**
VAS for pain (0-10 cm) 0.607
T0 6.8 (1.4) 6.8 (1.4)
T1 2.3 (2.4)* 2.0 (2.1)*
T4 2.9 (2.6)* 2.6 (2.6)*
T12 3.4 (2.8)* 3.0 (2.5)*
T32 4.5 (3.0)* 4.3 (3.2)*
T48 3.8 (3.2)* 3.8 (3.3)*
VAS for swelling (0-10 cm) 0.179
T0 3.9 (2.0) 3.8 (1.8)
T1 1.6 (1.7)* 1.0 (1.4)*
T4 1.1 (1.1)* 0.9 (1.4)*
T12 1.3 (1.3)* 0.7 (1.0)*
T32 1.6 (1.5)* 1.2 (1.4)*
T48 1.5 (1.7)* 1.0 (1.6)*
Morning stiffness 0.413
T0 14.2 (14.9) 32.5 (55.2)
T1 4.8 (12.9)* 1.9 (5.8)*
T4 6.2 (13.9)  4.1 (11.5)
T12 6.6 (22.0) 2.2 (5.0)
T32 12.2 (26.2) 26.9 (76.6)
T48 8.8 (15.5) 11.5 (33.3)
 Knee flexion (grade)  0.661
T0 116.1 (14.6) 115.03 (14.5)
T1 119.4 (16.7)* 121.97 (16.3)*
T4 120.5 (15.3)* 123.17 (16.4)*
T12 120.4 (12.5)* 121.93 (16.9)*
T32 117.6 (15.1) 120.3 (16.9)
T48 118.0 (15.2) 119.7 (18.0)
Knee extension (grade) 0.096
T0 7.7 (8.5) 3.1 (5.3)
T1 4.0 (5.9)* 1.8 (4.0)*
T4 3.5 (5.2)* 1.9 (4.0)*
T12 4.4 (5.8) 3.0 (7.3)
T32 6.5 (8.3) 3.3 (6.0)
T48 6.6 (8.7) 3.6 (6.8)
Knee circumference (cm) 0.875
T0 40.0 (3.8) 39.9 (3.3)
T1 38.4 (7.3) 39.3 (3.9)
T4 39.3 (4.0)* 38.9 (3.8)*
T12 39.7 (3.8)* 39.1 (4.3)*
T32 39.6 (4.0)* 39.2 (4.2)*
T48 39.3 (4.1)* 38.9 (4.5)*
TH group: triamcinolone hexacetonide (TH); Sm/TH group: 153SmPHYP 
+ TH; VAS: visual analog scale; SD=standard deviation; **ANOVA for re-
peated measurements; *p< 0.05 (intra-group p in relation to T0): Tukey 
multiple comparison test1191
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A femur fracture occurred in one patient from the Sm/TH 
group with risk factors for osteoporosis. This fracture was 
considered a casual event and occurred after 11 mo of follow-
up. There were no statistically significant differences between 
groups regarding events throughout the study (Table 5). 
One patient from the Sm/TH group required re-
infiltration of the knee with TH after 8 mo, and 2 patients 
from the TH group required re-infiltration of the knee after 
three and eight months from the intervention due to the 
recurrence of arthritis (p= 1.00). After three months, 27 
patients (14 from the Sm/TH group and 13 from the TH 
group; p= 0.795) modified the use of DMARDs due to 
activity of their disease. 
DISCUSSION
The effectiveness and cost benefit of RS for patients with 
chronic synovitis have not yet reached a consensus in the 
medical literature. Despite the fact that RS has a higher cost 
than IAI with GC, the benefit of its use is the impression of a 
greater response, longer duration of response in comparison 
to chemical synovectomy through corticosteroid use, and 
its use as an option for treatment of refractory synovitis.10,12 
In our study, 153SmPHYP was chosen because it is available 
for use in our country and for its properties.  153SmPHYP 
is a radionuclide with a half-life of 46.3 h and β- energy of 
0.29 MeV, resulting in a maximum penetration of 3.1 mm 
and therapeutic penetration of 0.7 mm into soft tissue.25,26 
The 153SmPHYP compound emits a small amount of gamma 
radiation, which is suitable for imaging by gamma camera 
equipment and is associated with low levels of leakage 
after injection, safe, and good tolerance.25,26,34 There is also 
a possible fibrotic action of this compound on the pannus, 
enabling more lasting control over inflammation. Therefore, 
use of this radioisotope is theoretically superior to the use 
of TH alone.
There are few controlled, randomized trials in the 
literature comparing RS with IAI of glucocorticosteroids. 
186Re is used for synovectomy of medium-sized joints and 
Table 3 - Knee function according to the Lequesne and HAQ 
questionnaires 
Time Points 
(weeks)
Sm/TH Group 
(n=30) 
Mean±SD
TH Group 
(n=30) 
Mean±SD
Inter-group 
p**
Lequesne index 0.889
T0 16.6 (3.2) 17.2 (2.8)
T1 11.8 (4.5)* 11.0 (5.0)*
T4 11.6 (4.8)* 11.2 (5.0)*
T12 12.0 (4.4)* 11.6 (5.1)*
T32 13.2 (4.8)* 13.4 (4.7)*
T48 13.2 (4.4)* 13.1 (4.5)*
HAQ 0.077
T0 1.3 (0.5) 1.6 (0.5)
T1 1.0 (0.5)* 1.2 (0.5)*
T4 1.0 (0.5)* 1.2 (0.6)*
T12 1.2 (0.5)* 1.4 (0.7)*
TH group: triamcinolone hexacetonide (TH); Sm/TH group: 153SmPHYP 
+ TH; SD=standard deviation; **ANOVA for repeated measurements; *p< 
0.05 (p intra-group p in relation to T0): Tukey multiple comparison test
Table 4 - Use of number of sodium diclofenac tablets and 
oral prednisone (doses)
Time Points 
(weeks)
Sm/TH Group 
(n=30) 
Mean±SD
TH Group 
(n=30) 
Mean±SD
Inter-group 
p**
NSAIDS, tablets/day (Mean±SD) 0.782
T0 0.63 (1.07) 0.63 (0.99)
T1 0.63 (0.99) 0.64 (0.87)
T4 0.80 (1.01) 0.77 (0.97)
T12 0.80 (1.04)* 1.07 (1.15)*
Prednisone, mg/day (Mean±SD) 0.064
T0 5.1 (6.0) 7.1 (5.3)
T1 5.3 (5.8) 6.6 (5.7)
T4 5.9 (5.5) 7.5 (5.0)
T12 5.5 (5.4) 7.6 (5.3)
TH group: triamcinolone hexacetonide (TH); Sm/TH group: 153SmPHYP + 
TH; NSAID= non-steroidal anti-inflammatory drug; SD=standard deviation; 
**ANOVA for repeated measurements; *p< 0.05 (p intra-group p in rela-
tion to T0): Tukey multiple comparison test
Table 5 - Distribution of the types of adverse effects and 
events between groups
ADVERSE EFFECTS Sm/TH Group 
(n=30)
TH Group 
(n=30)
Post-injection flare (T1) 2 2
Urticaria (T1) 2 0
Pruritus (T1, T4) 2 0
Chills (T1) 1 0
Headache (T1) 2 0
Rash on face (T1) 1 0
Sweating (T1) 1 0
Hot flashes (T1) 2 1
Hypertensive peak (T1, T4) 1 1
Insomnia (T4) 0 1
Swelling of lower limbs (T12) 1 0
Increased instability (T12,T48) 2 0
EVENTS Sm/TH Group 
(n=30)
TH Group 
(n=30)
Polaciury (T1) 0 1
Urinary tract infection (T1) 1 0
Acute sinus condition (T4) 0 1
Asthma episode (T4) 0 1
Vaginal Candidiasis (T32) 0 1
Femur fracture (T48) 1 0
Detached retina (T48) 0 1
TH group: triamcinolone hexacetonide (TH); Sm/TH group: 153SmPHYP 
+ TH; SD= standard deviation1192
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has been assessed in controlled, randomized prospective and 
retrospective trials that demonstrate its superiority to IAI 
of glucocorticosteroids.19,20,24 So far, there is no consensus 
about the superiority of RS with 169Er (used in small joints) 
over IAI of glucocorticosteroids.21,22 Synovectomy by  90Y 
has been studied in some controlled trials and has been 
shown to be superior to IAI of saline solution,10,13-15 but 
studies comparing it to IAI of glucocorticosteroids have 
had conflicting results.16-18 A systematic review regarding 
RS with  90Y concluded that there is no clear evidence of 
greater efficacy of  90Y over IAI of glucocorticosteroids 
despite its frequent use in cases of refractory synovitis.7 New 
radioisotopes such as Dysprosium-165 Ferric Hydroxide 
Macroaggregate (165Dy) and Holmium-166 (166Ho) have been 
developed, but their effectiveness and superiority have not 
yet been proven in clinical trials.32,33
The only controlled, double-blinded study of 153SmPHYP 
similar to the present study was carried out by O’ Duffy 
et al. (1999), who found no difference between the 
groups studied.26 However, sixty patients with different 
inflammatory arthropathies participated in this study and 
few assessment instruments were used.26 In the present 
study, only patients with RA participated and more objective 
instruments were used, rather than just scores, including 
those that assess inflammation, function, quality of life, 
subjective improvement, and adverse effects and events. 
The present study also found no statistically significant 
differences between groups for the diverse variables studied.
A trial with the same experimental design as the 
present study demonstrated through magnetic resonance 
a statistically greater reduction in synovitis of the knee in 
the group using IAI of TH alone in a three-month follow-
up.34 However, it only analyzed evolution through an 
imaging method and for a much shorter follow-up period.
Nonetheless, the findings of that study corroborate the 
impression that the addition of 153SmPHYP to TH does not 
increase the effectiveness of the glucocorticosteroids when 
injected into the intra-articular region.34
Studies on  153SmPHYP for RS describe no side effects 
attributed to the radioisotope.25-26 The present study found 
more adverse effects in the Sm/TH group than in the TH 
group, but the difference was only significant in the T1 
evaluation (p<0.015) and the effects were mild with a 
short duration and spontaneous remission. Most of the side 
effects were systemic and were also described for IAI of 
glucocorticosteroids.6 Post-injection flare occurred at an equal 
frequency in both groups, with an average duration of 2.25 d 
(1 to 4 d), and these effects did not persist until T1 evaluation.
In the present comparison study of RS with 153SmPHYP 
associated with TH and IAI of TH alone, no difference was 
found, which confirms the results of the study by O’ Duffy 
et al.26.
The results show that RS with  153SmPHYP associated 
with TH is not superior to IAI of HT alone, and that the 
positive effects may be attributed to the concomitant use of 
HT.13-16,18 
Some theories may explain the similar results between 
the groups studied:  153SmPHYP penetration may not have 
been effective for the knee, which is a large joint, or its 
dosage may have been too small. 
We conclude that IAI of 153SmPHYP at a dosage of 15 
mCi associated with TH was not superior to administration 
of TH alone for the treatment of synovitis of the knee in 
RA patients with a one-year follow-up. There is a need 
for studies with longer follow-up periods in order to more 
completely evaluate the benefit of  153SmPHYP in these 
patients’ knees. 153SmPHYP may be useful in medium-size 
joint, such as wrists, elbows, and ankles, because it exhibits 
tissue penetration similar to  186Re, which is also used in 
these joints.35 Thus, further studies assessing higher doses 
in the knees and similar doses in medium-sized joints are 
important for determination of the true effectiveness of RS 
through 153SmPHYP.
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